pd 131628 has been researched along with erythromycin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 1 |
| Cohen, MA; Huband, MD | 1 |
2 other study(ies) available for pd 131628 and erythromycin
| Article | Year |
|---|---|
Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Ciprofloxacin; Erythromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Quinolones; Streptococcus pneumoniae; Vancomycin; Virginiamycin | 1992 |
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clindamycin; Erythromycin; Fluoroquinolones; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma hominis; Mycoplasma pneumoniae; Naphthyridines; Quinolones; Tetracycline; Ureaplasma urealyticum | 1997 |